Probatebeta
Target

TRPV1

Transient receptor potential cation channel subfamily V member 1

As of the edition of 20 October 2026, TRPV1 (transient receptor potential cation channel subfamily V member 1, UniProt Q8NER1) has 16 drugs tested at it and 38 companies on the list, 12 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q8NER1
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
16
Disease areas
Nervous system; Bones, joints and muscles; Cancer; Immune system; Infections; Lungs and airways; Heart and blood vessels; Urinary and reproductive
Registered trials of its drugs
1,031

Drugs at this target

StatusCount
Marketed3
Went quiet10
Stopped3
Total16
DrugStatusFurthest phaseUS protection
AcetaminophenMarketedPhase 4none listed
CapsaicinMarketedPhase 4none listed
PAC-14028Went quietPhase 3none listed
AZD1386Went quietPhase 2none listed
ResiniferatoxinStoppedPhase 3none listed
SB-705498Went quietPhase 2none listed
CannabidivarinStoppedPhase 2none listed
MavatrepWent quietPhase 1none listed
TivanisiranWent quietPhase 3none listed
ZucapsaicinWent quietPhase 3none listed
DWP05195Went quietPhase 2none listed
SAF312StoppedPhase 2none listed

12 of 16 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A12
Route B5
Engaged18
Undetermined3
Total on the list38
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute A
Sorrento TherapeuticsRoute A
GSKRoute A

The other 35 companies at TRPV1

In the product

38 companies in all; 35 are not named here, and no score is.

See the 38 companies at TRPV1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at TRPV1

Other targets in nervous system